Pharmaceutical research provider Aquila BioMedical has moved to a purpose built ‘BioQuarter’, called Nine, ahead of a planned investment round.
The Edinburgh University spin-out, based in the Scottish capital, has been situated on campus at the Queens Medical Research Institute since it was founded in 2011. The company has indicated that an increased interest in its activities has paved the way for the move.
The firm supports academic experts and clinicians by conducting and delivering high-quality research. It offers clients access to research models on medical conditions such as multiple sclerosis, autoimmune disease, inflammation, and analgesia.
Clare Doris, chief operating officer for Aquila BioMedical, said: “Aquila is going from strength to strength. Our recent relocation to Nine will bring about a new chapter in the development of the company where we will be able to group our expanding team and build on our initial successes whilst retaining close links to the excellent scientific community at The University of Edinburgh.”
Howard Marriage, Aquila BioMedical’s chairman, added: “The company is now preparing for a significant investment round to capture the promising start and exploit its growing international client base. With the continuous evolution of drug discovery to specialist expert external providers we are well placed to accelerate growth in 2014. The investment will expand the range of service offerings across multiple autoimmune diseases, introducing fibrotic disease and support with increasing use of human cell systems for mechanism of action and biomarker discovery. The team are very committed to bringing our service business model of high quality experimental systems with integrated academic insight in study design and data interpretation to the wider drug discovery community”.
